TW200803882A - Ameliorant for metabolic syndrome - Google Patents

Abstract

To provide an ameliorant for metabolic syndrome with reduced adverse reaction and safe in daily intake over long period, having ameliorating efficacy on accumulation of visceral fat together with other risk factors, and to provide a prophylactic agent for arteriosclerosis, and to provide pharmaceuticals and foods comprising the same. The invention relates to the ameliorant for metabolic syndrome and the prophylactic agent for arteriosclerosis comprising a processed product of leaves of Eucommia ulmoides oliver and a processed product of a vegetable having blood sugar reducing action. The invention relates to the pharmaceuticals and foods comprising the same.

Description

200803882 (1) Description of the Invention [Technical Field of the Invention] The present invention relates to a metabolic syndrome improving agent containing a processed material of Eucommia ulmoides Oliv. Further, the present invention relates to a composition for oral administration containing a metabolic syndrome improving agent, a pharmaceutical composition, a food composition, and the like. [Prior Art] The increase in cardiovascular disease caused by excessive nutrition or lack of exercise is not only a problem in Europe and America but also in Asia. For the prevention of arteriosclerotic diseases such as myocardial infarction or cerebral infarction, it is conventionally focused on measures against hypercholesterolemia, and other risk factors may be used for each. However, in recent years, the background of satiety and exercise is insufficient. As a result of obesity, one person has accumulated a large number of risk factors, and the incidence of arteriosclerosis has been found out from so many risk factors syndromes (refer to the non-patent literature). 1)° Although this multi-risk factor syndrome has been called with various sorrows such as syndrome X, death quartet, insulin resistance syndrome, and visceral fat syndrome, the world has begun to unify these as metabolic syndrome, and Japan has defined metabolic syndrome. The diagnostic baseline. According to this criterion, it is consistent with visceral fat accumulation (85cm for men in the waist circumference and more than 90cm for women), which in turn is consistent with (1) lipid (more than 150mg/dL in blood or less than 40mg/dL in HDL), (2) In the case of fasting blood glucose (100 mg/dL or more) and (3) blood pressure (systolic blood pressure of 13 〇mmHg or more or diastolic blood pressure of 85 mmHg or more), two or more of (1) to (3) are diagnosed as metabolic syndrome ( 2) 200803882 Group (refer to Non-Patent Document 1). The drug therapy for metabolic syndrome has not been fully established, and the prescription for anti-fat drugs has been reviewed. However, Mazindol is known to be approved for use in Japanese medical insurance. The drug is attached to BMI35 and above and the insurance period is limited to 3 months. In addition, when individual drug treatment is applied to each risk factor of metabolic syndrome, there is a risk that the interaction caused by the drug may adversely affect the symptoms, such as the known antihypertensive agent | thiazide diuretic for reducing insulin sensitivity Chemical sugar. Adverse effects due to lipid metabolism (see Non-Patent Documents 2 and 3). Eucommiaulmoides Oliver is a deciduous woody genus of the genus Eucommia, which is derived from the central part of China. Eucommia ulmoides differs from plants commonly known as the genus Tea, except that they are completely free of caffeine. Eucommia leaves have been popularized since the 1980s as a beverage. The bark of Eucommia ulmoides is used as a medicine, and it is used as a Chinese herbal medicine effective for "hypertension, low back pain, phlegm pain, kidney disease, liver disease, stress, diminished energy, diuresis, and forgetfulness". Since natural foods or Kampo medicines generally have the advantage of having fewer side effects, the increase in lifestyle-related diseases has increased in recent years, and this effectiveness has been attracting attention. In the above-mentioned eucommia, there are several reports on the examples of the activity of the lipase-inhibiting activity of the eucommia leaf component (refer to Patent Documents 1 to 5) [Patent Document 1] JP-A-2005-28995 0 [Patent Document 2] Japanese Laid-Open Patent Publication No. JP-A No. Hei. No. Hei. No. Hei. No. Hei. No. Hei. 275077 [Non-Patent Document 1] Guidelines for the diagnosis and treatment of obesity and metabolic syndrome, medicalview, 2005, pages 10 to 11 [Non-Patent Document 2] Guidelines for the diagnosis and treatment of obesity and metabolic syndrome, medicalview, 2005, 205-206 [Non-Patent Document 3] Guidelines for the diagnosis and treatment of obesity and metabolic syndrome, Medicalview, 2005, pp. 207 to 209 [Invention] [Disclosure of the Invention] [Problems to be Solved by the Invention] The present invention provides natural materials as A raw material, a small amount of side effects, and safe for long-term ingestion, and a metabolic syndrome improver and an arteriosclerosis preventive agent, which are not only for the accumulation of visceral fat but also for other risk factors. For the purpose of medicine or food. [Means for Solving the Problems] In order to solve the above-mentioned problems, the inventors of the present invention have found that the metabolism syndrome is improved in the composition containing the processed material of the Dugong leaf, and the present invention has been completed. That is, according to one form of the present invention, a metabolic syndrome improving agent comprising a processed material of Eucommia ulmoides leaves is provided. According to another aspect of the present invention, there is provided a metabolic syndrome improving agent comprising a eucommia leaf processed product and a plant processed product having a blood sugar lowering effect of -6 - (4) (4) 200803882. Here, the blood sugar lowering action of the plant processed product may be caused, for example, by an α-glucosidase inhibitory action. Further, examples of the plant processed material include Salacia, mulberry leaves, Banaba leaves, guava, yae, olive leaves, bitter gourd, apocynum, and sap leaves. (G ymnemasy Iv estre ), Western ginseng, Kochia scoparia, ginseng, Mate tea, Egyptian wild sesame (

Extracts and originals of Cor chorus olitorius), He Ye, Ipomoea batatas, Tianqi, Rhodiola, Sargassum, Scutellaria, Polygonatum, Mangosteen, Equisetum Arvense, Hawthorn, Ganoderma Lucidum Dry matter. The plant processing materials suitable for use in the present invention are the Sarah extract and the mulberry leaf extract. Salarwood extract and mulberry leaf extract can be obtained by purchase, and salam extract can be used in the present invention, for example, Sarah Extract D (produced by Tada Philosophy Co., Ltd.) and mulberry leaf extract, such as mulberry leaf extract. Powder (manufactured by Japan Powder Pharmaceutical Co., Ltd.). According to another aspect of the present invention, the above plant processed product is selected from the group consisting of a poorly digestible dextrin and a mulberry leaf processed product having a defined metabolic syndrome improving agent. The indigestible dextrin used herein is not particularly limited, and for example, a water-soluble food obtained by treating a starch derived from a plant (for example, corn, potato, etc.) with a digestive enzyme (amylase, glucoamylase, etc.). Fibers can also be used. According to another aspect of the present invention, there is provided a defined metabolic syndrome improving agent for the above-mentioned Eucommia ulmoides leaf extract. The eucommia leaf processing product is not particularly limited, and the extraction solvent used for producing the extract is (5) (5) 200803882, for example, water, ethanol, methanol, a mixed solvent thereof, or the like can be used. According to one aspect of this aspect of the invention, the eucommia leaf processed product may be a step comprising the step of frying the Eucommia leaf; the step of extracting the Eucommia leaf from water; and the Eucommia obtained by the method of concentrating the extract. Leaf water extract. According to another aspect of this aspect of the invention, the eucommia leaf processed product may be a step comprising steaming Eucommia leaves; a step of eucommia ulmoides leaves; a step of drying Eucommia leaves; a step of roasting Eucommia leaves; a step of Eucommia ulmoides leaves; and an aqueous extract of Eucommia ulmoides leaves obtained by the method of concentrating the extract. According to another aspect of the present invention, there is provided a defined metabolic syndrome improving agent of the above-mentioned Eucommia ulmoides processed material which is a pulverized material of dried Eucommia ulmoides leaves. According to another aspect of this aspect of the invention, the above-mentioned Eucommia ulmoides leaf processed product may be obtained by a step comprising steaming Eucommia leaves; a step of eucommia ulmoides leaves; a step of drying Eucommia leaves; and a manufacturing method of the step of pulverizing Eucommia leaves Dried Eucommia leaf pulverized material. According to another aspect of this aspect of the invention, the eucommia leaf processed product may be a step comprising steaming Eucommia leaves; a step of eucommia ulmoides leaves; a step of drying Eucommia leaves; a step of roasting Eucommia leaves; and pulverizing Eucommia leaves The dried Eucommia ulmoides leaf pulverized material obtained by the method of the steps. According to another aspect of this aspect of the invention, the eucommia leaf processed product may be a step comprising steaming Eucommia ulmoides leaves; a step of drying the Eucommia ulmoides leaves under stirring and/or rolling; and irradiating the eucommia leaves with far infrared rays Dry eucommia leaf pulverized material obtained by the method for drying the eucommia leaf step -8 - (6) (6) 200803882 According to another aspect of this aspect of the invention, the above-mentioned eucommia leaf processed product may comprise steamed eucommia leaf a step of drying the eucommia leaves under stirring and/or rolling; a step of homogenizing the water in the leaves of Eucommia; a step of drying the leaves of Eucommia; a step of pulverizing the leaves of Eucommia; and irradiating the far infrared rays with the leaves of Eucommia The dried Eucommia ulmoides leaf pulverized material obtained by the method for drying the Eucommia leaves. According to another aspect of this aspect of the invention, the eucommia leaf processing product may be a step comprising steaming Eucommia ulmoides leaves; a step of drying the Eucommia ulmoides leaves under agitation and/or squeezing; and uniforming the water in the Eucommia ulmoides leaves a step of drying the eucommia leaves under stirring and/or rolling, a step of drying the leaves of Eucommia ulmoides; a step of pulverizing the leaves of Eucommia ulmoides; and a method for producing a step of drying the leaves of Eucommia ulmoides Oliv. The dried Eucommia leaves are smashed. In the above-described form, the method for pulverizing the dried Eucommia ulmoides leaves is not particularly limited, and the method for processing the pulverized material used for producing the pulverized material is, for example, a rotary pulverizer, a dial-type mill, and a collision type pulverizer. , a pulverizer such as a jet mill. According to another aspect of this aspect of the invention, the step of treating the Eucommia ulmoides leaves is carried out by the step of frying the Eucommia ulmoides leaves; the step of drying the Eucommia ulmoides leaves under agitation and/or rolling; a step of drying the Eucommia leaves by infrared rays; and a Eucalyptus leaf green powder obtained by a method for producing a powder of Eucommia ulmoides by a jet mill. According to another aspect of this aspect of the invention, the eucommia leaf processing product may be a step comprising steaming Eucommia ulmoides leaves; a step of drying the Eucommia ulmoides leaves under agitation and/or squeezing; and uniforming the water in the Eucommia ulmoides leaves Step of drying; dry-9-(7) (7)200803882 step of drying Eucommia leaves; step of pulverizing Eucommia leaves; step of drying Eucommia leaves by irradiating far infrared rays to Eucommia leaves; and Eucommia leaves by jet mill Eucommia leaf powder obtained by the method of producing a powder. According to another aspect of this aspect of the invention, the eucommia leaf processing product may be a step comprising steaming Eucommia ulmoides leaves; a step of drying the Eucommia ulmoides leaves under agitation and/or squeezing; and uniforming the water in the Eucommia ulmoides leaves a step of drying the leaves of Eucommia ulmoides under stirring and/or rolling; a step of drying the leaves of Eucommia ulmoides; a step of pulverizing Eucommia ulmoides leaves; a step of irradiating the dried Eucommia leaves with far infrared rays on Eucommia leaves; and pulverizing by jet blasting Eucommia leaf powder obtained by the method for producing a step of making Eucommia ulmoides leaves. In the above-described form of the present invention, the Eucommia ulmoides leaf used in the step of steaming the Eucommia ulmoides leaves may also be uncut. According to another aspect of this aspect of the present invention, the Eucommia ulmoides leaf water obtained by the above method, or the eucommia green powder produced by the above method, and the eucommia leaf water obtained by the method for obtaining the water extract may be further included. Extracts. According to another aspect of the present invention, there is provided a defined metabolic syndrome improving agent which is a mixture of the above-mentioned Eucommia ulmoides leaf extract and the pulverized material of dried Eucommia ulmoides leaves. Here, the above-mentioned Eucommia ulmoides leaf extract and dried eucommia leaf pulverized material can be used as defined. According to another aspect of the present invention, there is provided a metabolic syndrome improving agent which is defined by the amount of one day, for example, containing 75 mg or more, preferably 85 mg or more, and 99 mg or more of geniposidic acid. -10- (8) 200803882 The metabolic syndrome improving agent of the present invention can also be used for preventing arteriosclerosis and preventing arteriosclerotic diseases (for example, ischemic heart diseases such as cerebral infarction, myocardial infarction or angina, large aneurysms, Aortic dissociation, obstructive aneurysm cirrhosis, etc.). Further, according to another method of the present invention, a pharmaceutical, a pharmaceutical composition, a food, a food composition or an oral ingestion composition containing a modified metabolic syndrome improving agent is provided. Here, the food is not particularly limited, and may be, for example, a functional food, a health food, a health supplement food, a nutritional supplement food, an insurance functional food, a specific insurance food, or a nutritious functional food, in the packaging, container, etc. of the food. It also shows functions such as "metabolic syndrome improvement effect" and "arteriosclerosis prevention effect". [Effects of the Invention] In addition to the effect of reducing visceral fat, the metabolic syndrome improving agent of the present invention can also obtain other complex risk factors (1) to reduce the effect of φ blood neutral fat, and (2) to reduce fasting. Any of the effects of blood sugar sputum and (3) the effect of lowering blood pressure. For example, the metabolic syndrome improving agent of the present invention can have an effect of reducing visceral fat, an effect of reducing blood neutral fat, and an effect of suppressing blood sugar at an empty stomach. At least one of the effects obtained by combining the Eucommia ulmoides leaf processed product and the plant processed product having a blood sugar lowering effect can be more excellently obtained by separately administering the Eucommia ulmoides leaf processed product and the plant processed product having a blood sugar lowering action ( Multiplication effect -11-(9) (9)200803882 [The best mode for carrying out the invention] The present invention will be more specifically described below. The eucommia leaf processing product of the present invention is a Eucalyptus leaf or Eucommia ulmoides dry leaf. It is prepared by using raw materials. Here, Eucommia ulmoides leaves are also referred to as Eucommia leaves before drying after harvesting, and may be produced by cultivated plants or natural harvested. For example, the leaves of the leaves used in the year before the leaves were used. The harvesting period can be used from April to October, and from May to August, and from July to August, the steaming step of the above-mentioned Eucommia leaves is used as a commercial steamer or autoclave. It can be carried out by the method generally carried out in the technical field. For example, the eucommia leaves are spread on the mesh belt, so that the processing chamber filled with the pressureless steam supplied by the boiler can be steamed to treat the Eucommia leaves. Temperature is not A particular limitation, for example, depending on the size of the leaves of Eucommia ulmoides, may suitably be selected from the range of 90 to 120 ° C, preferably from 95 to 10 10 ° C, particularly preferably from 100 to 10 10 ° C. In addition, the range of steaming time It is also suitably selected for 10 to 240 seconds, preferably 20 to 180 seconds, and particularly preferably 20 to 120 seconds. In addition, the range of the amount of vapor used may be appropriately selected, for example, 200 to 70 L/min, and preferably 170 to 100 L/. The treatment amount of the cooked leaves is not particularly limited in view of the moisture content of the leaf, and may be appropriately selected, for example, 3 to 10 kg/min, preferably 4 to 8 kg/min, and preferably 5 to 7 kg/min. The ripening step has a component which inactivates the enzyme which discolors the brown leaves of Eucommia ulmoides and which is easy to preserve the leaves of Eucommia ulmoides; and the leaves of Eucommia ulmoides are soft, and it is easy to carry out the subsequent mashing step, etc. For example, a commercially available machine 'rough-12-(10) 200803882 machine or a smashing machine can be used. For example, as a commercially available machine, a 60Kg type machine manufactured by Terada Manufacturing Co., Ltd. can be used. Excess water and evenly adjusted in the leaves of Eucommia Further, it is easy to extract the components unique to Eucommia ulmoides. This step is preferably carried out under heating, but it is preferably carried out without heating. Further, the time required for this step is not particularly limited, and may be appropriately selected. The range is, for example, 10 to 80 minutes, preferably 20 to 60 minutes, and particularly preferably 25 to 30 minutes. The amount of the treatment is not particularly limited, and the range can be appropriately selected, for example, the moisture content is 25 to 40 kg. Preferably, it is 30 to 35 kg, preferably 32 to 3 3 kg. The water content of the Eucommia leaves obtained by this step is, for example, 25 to 40% on a dry basis, preferably 25 to 35%, and 25 Up to 30% is especially good. The above steps of drying the Eucommia leaves can be carried out, for example, by exposure to sunlight. The time for solar exposure is not particularly limited, and a range can be appropriately selected, for example, 96 to 120 hours, preferably 96 to 1 14 hours, and particularly preferably 96 to 12 hours. Further, the drying step can be carried out using a commercially available dryer φ. The drying method by the dryer is not particularly limited, and is carried out, for example, by a dryer ND 120 manufactured by Terada Manufacturing Co., Ltd. The hot air temperature here is not particularly limited, and a range can be appropriately selected, for example, 70 to 100 ° C, preferably 85 to 95 t. Further, the time required for this step is not particularly limited, and a range can be appropriately selected, for example, 5 to 80 minutes, preferably 10 to 80 minutes, and particularly preferably 20 to 80 minutes. The water content of the Eucommia ulmoides leaves obtained by this step is not particularly limited, and the range can be appropriately selected, for example, the water content is 5% or less, and the water content is preferably 3% or less, and the water content is preferably 2% or less. -13· (11) (11)200803882 The above-mentioned roasted eucommia leaf step is not particularly limited and can be carried out using a commercially available roaster. The method of roasting in this step is not particularly limited, and it can be carried out, for example, by a hot air type rotary drying and heating machine manufactured by Yokoyama Manufacturing Co., Ltd. Further, the time required for this step is not particularly limited, and a range can be appropriately selected, for example, 30 to 50 minutes, preferably 30 to 45 minutes, and particularly preferably 3 to 40 minutes. Further, the baking temperature in this step is not particularly limited, and a range can be appropriately selected, for example, 100 to 140 ° C, preferably 120 to 140 t: particularly preferably 130 to 140 ° C. The water content of the eucommia obtained by this step is, for example, 8% or less on a dry basis, preferably 4% or less, and particularly preferably 2% or less. The step of obtaining the above aqueous extract of Eucommia ulmoides leaves may be appropriately selected from, for example, 5 to 50 kg, preferably 10 to 3 kg, and preferably 15 to 20 kg, with respect to 1 kg of water of the Eucommia leaf processed product. The extraction temperature can be appropriately selected, for example, from 8 5 to 9 8 ° C, preferably from 90 to 95 ° C. The extraction time is not particularly limited and may be appropriately selected, for example, from 1 Torr to 1 20 minutes, preferably from 20 to 90 minutes, and particularly preferably from 30 to 60 minutes. The filtered extract can be carried out using, for example, a filter of 30 to 200 mesh. The filtrate can be allowed to stand for a certain period of time before being concentrated. The impurities can be removed by removing the precipitate which has occurred by standing. The standing time is not particularly limited and may be suitably selected, for example, from 1 to 24 hours, preferably from 6 to 20 hours, and particularly preferably from 8 to 18 hours. The temperature at the time of standing is not particularly limited, and may be suitably selected, for example, from 0 to 35 ° C, preferably from 16 to C, particularly preferably from 2 to 8 ° C. The concentration of the extract obtained as a filtrate can be carried out by the method generally used in the art -14-(12) (12)200803882, for example, a rotary evaporator can be used. The concentration step can be appropriately selected, for example, 20 to 140 mmHg, preferably 30 to 120 mmHg, and 40 to 100 mmHg, particularly preferably under reduced pressure, and the temperature range can be appropriately selected, for example, 30 to 80 T: It is preferably 35 to 70 ° C, preferably 40 to 60 ° C. From the concentration step, the volume ratio to the extract is, for example, 5 to 8 %, preferably 5.6 to 7.5%, particularly preferably 6 to 6.6%. The obtained concentrate can be directly used as the aqueous extract of Eucommia ulmoides leaves of the present invention, and can be subjected to treatment such as centrifugation, heat sterilization or the like. The centrifugation separation is carried out using a commercially available centrifugal separator, which can be carried out by a method generally used in the art. For example, a rotary type centrifugal separator is used for the batch type, and a multi-chamber centrifugal separator, a decanter centrifuge, a cylindrical centrifugal separator, or the like is used for the flow type. The conditions for the centrifugal separation are not particularly limited, and may be suitably selected from, for example, a batch centrifuge, the number of rotations is from 1 Torr to 3 1 00 rpm, preferably from 1,500 to 2,500 rpm, and particularly preferably from 1,800 to 2,000 rpm. For example, g値 is 210 to 2010g, preferably 470 to 13 10g, and particularly preferably 68 to 840g; and for example, the treatment time is 10 to 60 minutes, preferably 15 to 40 minutes, and preferably 20 to 30 minutes. Under the appropriate selection conditions. In the case of a continuous pass type centrifugal separator, it is preferably from 100 to 400 mesh, preferably from 150 to 350 mesh, and preferably from 200 to 300 mesh. After the centrifugation, the supernatant recovery is carried out by water supply, filtration of the algae as a filter aid, etc.

The warming sterilization is performed by heating to, for example, 75 to 100. (:, preferably 80 to 9 5 ° C -15- (13) 200803882 is preferably performed at 85 to 90 ° C. The treatment time for heat sterilization is suitably selected from, for example, 60 It is preferably from 90 to 220 minutes to 240 minutes, and preferably from 120 to 180 minutes. The concentration ratio of the obtained aqueous extract of Eucommia ulmoides leaves is relative to the volume ratio of the extract, for example, 5 to 7.5%. 5 to 5 to 7% is preferred, and 6 to 66.5 % is particularly preferred, for example, 6.5 %. The obtained eucommia leaf water extract has a geniposide content of 6 to _ 40 mg/g to 15 Preferably, it is preferably from 28 to 37 mg/g, for example, 30 mg / g. The concentrated extract is dried by spray drying, freeze drying, or the like, which is usually used in the technical range. A powder of Eucommia ulmoides leaf water extract. The extract powder can be extracted from the Eucommia leaf before water extraction after 1 kg, to obtain, for example, 200 to 600 g, preferably 200 to 400 g. The obtained Eucommia ulmoides leaf water extract The powder has a geniposide content of 40 to 100 mg/g, preferably 50 to 90 mg/g, more preferably 60 to 80 mg/g, for example, φ 77 mg/g. The obtained Eucommia leaf water extract powder is The content of glucoside is 30 to 60 mg/100 g, preferably 35 to 55 mg/100 g, more preferably 40 to 50 mg/l 〇〇g, for example 47 mg/100 g. Eucommia leaf system obtained from the above-mentioned step of drying Eucommia leaves The step of preparing the powder by the jet mill can be directly carried out, and the preliminary pulverization can be carried out before the step. The method of the pseudo pulverization is not particularly limited and can be carried out, for example, using a commercially available pulverizer. The pulverization method is not particularly limited. For example, it can be carried out by C〇r〇Plex250Z type manufactured by Takino Industry Co., Ltd., and the size of the Eucommia leaf obtained by this step is, for example, 1 50 μm to -16-(14) (14) In the case of 200803882, it is preferably ΙΟΟμπι or less, and preferably 75 μm or less. In the present invention, the step of pulverizing Eucommia ulmoides leaves powder (for example, a powder having an average particle diameter of 3 to 14 μηη) by a jet mill is not particularly limited. For example, it can be carried out using a commercially available jet mill. Here, the compressed air used in the jet mill can be heated, and the temperature range can be appropriately selected, for example, 70 to 150 ° C, and 90 to 150 ° C. should It is particularly preferable to heat the compressed air for pulverization, and it has the advantage of being heat-sterilized in this step, and the discoloration after processing of the Eucommia ulmoides powder powder is extremely small. In addition, in order to increase the particle size of the powder Uniformity. The obtained Eucommia ulmoides leaf powder has an average particle size range, for example, 3 to 14 μm, preferably 4 to 8 μm, and particularly preferably 4 5 to 6 μm, for example, 5 μm. Further, the eucommia leaf powder obtained in this step has a medium ruthenium particle diameter range, for example, 2 to 14 μm, preferably 2 to 8 μm, and more preferably 4 to 5 μm, for example, 5 μm. In addition, the Eucommia leaf powder obtained in this step has the highest probability particle diameter range, for example, 2 to 32 μm, preferably 2 to 9 μm, and preferably 4 to 6 μm, for example, 5 // m °. The fixed input air volume is 5.5m3/min, and the crushing pressure is 0.6Mpa, and the range can be appropriately selected from 1 to 12kg/hour, preferably from 1 to 8kg/hour, and particularly preferably from 1 to 6kg/hour. The water content of the Eucommia ulmoides obtained by this step is, for example, 6% or less on a dry basis, preferably 4% or less, and particularly preferably 2% or less. The term "metabolic syndrome improving agent" as used in the present specification is not particularly limited, and means that, in addition to the effect of reducing visceral fat, for example, (1) the effect of reducing blood neutral fat, (2) Reduce the effect of -17-(15) (15)200803882 on the effect of fasting blood glucose and (3) the effect of lowering blood pressure. For example, the metabolic syndrome improving agent in the present invention may have an effect of reducing visceral fat, an effect of reducing blood neutral fat, and an effect of suppressing blood sugar at an empty stomach. The metabolic syndrome improving agent and the atherosclerosis preventing agent of the present invention are not particularly limited, and other agents used for improving metabolic syndrome, such as a fat absorption inhibitor, a therapeutic or prophylactic agent for obesity, and anti-lipemia may be used. A prophylactic or therapeutic agent, and a therapeutic or prophylactic agent for diabetes, hypertension, and the like. The metabolic syndrome improving agent and the arteriosclerosis preventing agent of the present invention can be used as an active ingredient of a pharmaceutical composition. The pharmaceutical composition is in various dosage forms, for example, for oral administration, and can be prepared into tablets, capsules, powders, granules, nine doses, liquids, emulsions, suspensions, solutions, alcohols, syrups. , extractant, expectorant, etc., for example, sputum can be made into a milk, cream, jelly, gel, paste, ointment, etc., but not limited to this. The pharmaceutical composition may contain various components generally used, for example, one or more of the above-mentioned pharmaceutically acceptable excipients, disintegrating agents, diluents, slip agents, flavoring agents, coloring agents. , sweeteners, flavoring agents, suspending agents, wetting agents, emulsifiers, dispersing agents, adjuvants, preservatives, buffers, binding agents, stabilizers, coating agents, and the like. Further, the pharmaceutical composition of the present invention may be in the form of a sustained or sustained release dosage form. The administration amount of the metabolic syndrome improving agent and the arteriosclerosis preventing agent of the present invention can be appropriately selected depending on the body type, age, physical condition, degree of disease, elapsed time after onset, and the like, and the pharmaceutical composition of the present invention can be appropriately selected. -18- (16) (16)200803882 Contains a therapeutically effective amount and/or a prophylactically effective amount of a metabolic syndrome improving agent and an agent for preventing arteriosclerosis. For example, as the eucommia leaf pulverized material or the water extract of the present invention, it is generally used in an amount of from 10 to 500 mg / day / adult, preferably from 100 to 5000 mg / day / adult. The administration of the pharmaceutical composition may be administered in a single administration or in multiple administrations, and may be used in combination with other agents such as other metabolic syndrome improving agents and arteriosclerosis preventing agents. The food of the present invention comprises a liquid dip and a solid food. This food can be used as a component of the Ministry of Medicine, other foods and drinks, food additives, and the like. In addition, the composition for oral ingestion in the present specification can be used as a functional food, and can also be used as a component of a pharmaceutical product, a medical external product, a food or drink, a food additive, or the like. According to this use, the food or oral ingestion composition having the metabolic syndrome improving agent and the arteriosclerosis preventing agent of the present invention can be ingested daily and continuously, and the metabolic syndrome can be effectively improved, and arteriosclerosis can be effectively prevented. Arteriosclerotic disease. Examples of foods or beverages containing the metabolic syndrome improving agent and the arteriosclerosis preventing agent of the present invention include functional foods, health foods, health supplement foods, and nutritional supplement foods (nutrition oral liquids) having a lipolytic enzyme inhibitory effect or an obesity inhibiting effect. Etc.), insurance functional foods, specific insurance foods, nutritious functional foods, general foods (juice, snacks, processed foods, etc.). The food or beverage in the present specification may contain, as an additive, an inorganic component such as iron or calcium, various foods such as vitamins, oligosaccharides and chitosan, proteins such as soybean extract, and lecithin. Sugars such as lipids, sucrose and lactose, aspartame, potassium acesulfame, stevia, s--19-(17) (17) 200803882 thaumatin, saccharin, sodium saccharin, etc. . [Embodiment] [Embodiment] Hereinafter, a preferred embodiment of the present invention will be described in more detail, but the present invention is not limited to the embodiments. [Example 1] Preparation of Eucommia ulmoides leaf extract (1) Production of Eucommia ulmoides leaf processed material for water extraction The eucommia leaf processing product for water extraction was carried out in accordance with the description of Example 2 of JP-A-8-173110. 5 kg of Eucommia ulmoides leaves were cooked from a conveyor belt cooker for Japanese tea production at 10 ° C for 90 seconds. The input port of the conveyor belt digester is put into the machine, and when the conveyor belt is moved, the steam from the upper and lower steam supply device is contacted, and steamed at n 0 °c for 90 seconds (1) spread on the mesh conveyor belt to spread the Eucommia leaf, borrowing The Eucommia ulmoides leaves can be steamed and processed by passing through a processing chamber filled with non-pressure steam supplied by the boiler. For example, a conveyor belt type 1000 of a ground type 1500 and a mesh conveyor belt for a leaf machine manufactured by Miyamura Iron Works Co., Ltd. can be used. Next, the steamed eucommia leaves were immersed for 30 minutes, and the mash was dried at 80 ° C for 5 hours using a dryer to make the water content 5%. The color of Eucommia leaves is greenish brown after steaming, but changes to a dark brownish brown with drying. Thereafter, using a frying machine (IR - 1 0 S P type: Terada Manufacturing Co., Ltd.), the mixture was roasted at 1 l ° C for 30 minutes to obtain a sample of the processed Eucommia ulmoides leaf extract of 2 kg of water. -20- (18) 200803882 (2) Preparation of extract of Eucommia ulmoides leaves A sample of Eucommia ulmoides leaves treated with 1 kg of water was added to 15 kg of its hot water, and it was extracted with 90 for 30 minutes to obtain 14 kg. Thereafter, it was filtered using a 150 mesh filter, and the filtrate was cooled to 5 Torr and left for 1 night. The supernatant was taken out, and the filtrate was concentrated under reduced pressure at 50 ° C to give lkg. The concentrate is a centrifugal separator made by Kubota Co., Ltd.

The KS8000 was treated by centrifugation at a rotational speed of 1 800 rPm to remove the precipitate, and the resulting supernatant was heat-sterilized (85 ° C, 2 hours) to obtain an aqueous extract of Eucommia ulmoides leaves. The concentrated extract was dried by spray drying to obtain a brown powder of eucommia leaf water extract powder (300 g). [Example 2] Preparation of Eucommia ulmoides leaf powder (1) Production of dried Eucommia ulmoides leaf system 1 20 kg of Eucommia ulmoides leaves, steamed with a conveyor belt cooker, stirred with a leaf beater and dried under a pressure, with a 揉φ 捻 machine The water in the leaves of Eucommia is homogenized. Thereafter, the mixture was stirred with a leaf beater and dried under pressure to homogenize the water in the leaves of Eucommia ulmoides. The thus treated Eucommia leaves 'dryed by a re-drying machine to obtain dried Eucommia leaves. The conditions in each step are as follows: Conveyor belt digester: The amount of steam is 140 L/min, the cooking time is 80 sec. The vapor temperature is 100 to ll 〇 °C. Leaf beater: The number of rotations was 36 rpm The obtained 30 kg of dried Eucommia leaves were pulverized into 1.4 mm to 2.8 mm by the UGC-280 type manufactured by Horai Co., Ltd. Next, using a far-infrared roasting machine, the upper and lower layers of the ceramic heater-21-(19)(19)200803882 were respectively irradiated with 1 lamp at a passing speed of 45 seconds, and roasted at about 200 ° C. 26 kg of roasted and dried Eucommia leaves were obtained. (2) Preparation of Eucommia ulmoides leaf powder 26 kg of roasted and dried Eucommia ulmoides leaves obtained in Example 2 (1) were pulverized into 75 μηι by Cor〇plex 25 0Z manufactured by Kanye Industry Co., Ltd., and fixed by a jet mill. The pressure was 〇6 Mpa, which was finely pulverized at a feed rate of 4 kg/hour. When this was pulverized by a jet mill, the compressed air was heated to 150 ° C to obtain 0.98 kg of dried Eucommia leaf powder. [Example 3] Evaluation test of metabolic syndrome improvement effect of Eucommia ulmoides leaf extract (1) Preparation of test food As a test food, the powder of Example 1 containing 50% by weight or more was blended, and 4 3 · 5 wt% was added. Powder-reduced maltose water (ama 11 y MR - 1 00: manufactured by Toka Chemical Co., Ltd.) as an excipient, 5% by weight of sucrose fatty acid ester (RYOTO Suger Ester S-3 70F: manufactured by Mitsubishi Chemical Foods Co., Ltd.) 1.7% by weight of particulate cerium oxide (Carplex FPS - 500 : DSL Japan) ingots (333 mg per ingot, 10 mg of geniposide), coated with a small amount of surface agent (Lacglaze 20E: Japan SHELLAC Industrial Co., Ltd. After drying, the tablet is prepared. (2) Test method The sfomo test was conducted by public test, and the ingestion period was 4 weeks, and the adult male -22-(20) (20) 200803882 totaled 6 females as the test subjects. The tablet (the total content of geniposide acid was 90 mg) of Example 3 (1) was ingested by the tester for one day. In addition, the tester requested not to change the daily life of eating habits, smoking, and exercise, except for the daily intake of test foods. The measurement system was performed twice at the start of the test and after 4 weeks of ingestion, and blood neutral sputum, fasting blood glucose sputum, blood pressure, and waist circumference were carried out as follows. The blood drawing method is before the meal in each period (in the morning on an empty stomach; after a day of dinner, after a hunger strike for 1 hour), each time the blood is drawn by about 10 ml (15 ml after the start of the test food), the blood is dispensed in the prescribed 4 Sampling tube. After the blood pressure was measured for a minimum of 5 minutes, the systolic blood pressure at the time of sitting was measured twice by an automatic sphygmomanometer (HEM - 1 000 manufactured by Omron). However, when the difference between the second and first systolic pressures is 10 mmHg or more, the measurement is performed again, and the measurement is performed until the range is stabilized. The mean sputum measured twice by the blood pressure sputum automatic blood pressure monitoring device. The measurement of the waist circumference is in the position of the navel, and the two legs stand close together. Both hands naturally hang down on both sides of the body, eliminating the tension of the stomach, and measuring when the natural exhalation is over. In addition, the measurement system uses a non-stretchable cloth scale. All assays are expressed as mean 値. In addition, for the comparison of the start of ingestion and the fourth week of ingestion, a paired t-test (3) was performed. The results are shown in Table 1. From the ingestion of 9 tablets, the tablet of -23-(21) 200803882 described in Example 3 (1) (the total content of geniposide acid was 90 mg) was used as a portion of the day, compared with the start of ingestion, and the blood was collected 4 weeks later. There is a tendency for the reduction of sexual fat, systolic pressure and waist circumference. [Table 1] Table 1 Metabolic syndrome of Eucommia ulmoides leaf extracts Item Neutral blood fat (mg/dL) after 4 weeks of ingestion 1 19.2 112.8 Systolic blood pressure (mmHg) 123.8 12 1.0 Fasting blood glucose 値 (mg/ dL) 8 6.2 9 1.0 Waist circumference (cm) 85.9 85.0 [Example 4] Evaluation test for metabolic syndrome improvement effect of Eucommia ulmoides leaf powder (η-modulation test food test food product uses the powder of Example 2. (2) Test method test The method was carried out in the same manner as in Example 3, and was carried out by 5 male and female adults. The tester was allowed to ingest 3 g of the powder of Example 4 (1) per day during the ingestion (the geniposide content was 8 5 (mg) The results are as shown in Table 2. The powder described in Example 4 (1) was taken as a one-day meal (the content of geniposide was 85 mg), which was compared with the start of ingestion. After the week, the blood fat, systolic blood pressure, and waist circumference decreased by -24- (22) 200803882. [Table 2] Table 2 Metabolic syndrome improvement effect of Eucommia ulmoides powder. Medium neutral fat (mg/dL) 138.0 10 4.0 Pressure (mmHg) 119.8 117.6 fasting blood glucose level (mg / dL) 8 1.6 91.0 Waist (cm) 84.0 8 1.0

[Example 5] Evaluation test for the improvement of the metabolism of the Eucommia ulmoides leaf extract, Eucommia ulmoides leaf powder and mulberry leaf extract (1 〇) The test food was prepared by the following method. The powder of Example 1 containing 55.6 wt% or more was contained, and 23.3% by weight or more of the powder of Example 2 was contained, and 10% by weight or more of mulberry leaf extract powder (manufactured by Nippon Powder Pharmaceutical Co., Ltd.) was contained. 5% by weight of crystalline cellulose (CEO LUS FD — 301: manufactured by Asahi Kasei Chemicals Co., Ltd.)

The weight % of purified water and 35% by weight of ethanol were kneaded, and dried by a dryer at 45 ° C for 15 hours to evaporate the purified water and ethanol. After granulation, 5·7 wt% of sucrose fatty acid ester (RYOTO Suger Ester S - 3 70F: manufactured by Mitsubishi Chemical Foods Co., Ltd.) and 1.8 wt% of particulate cerium oxide (1 wt%) were mixed.

CarplexFPS FPS - 5 00 : D S L J ap an Co., Ltd.), obtained from ingots (300 mg per ingot, 11 mg of genistein per ingot) at 22·2 wt. Yeast wrap (manufactured by KIRIN Beer Co., Ltd.) and 〇·36 -25- (23) 200803882 A mixture of glycerin (manufactured by Kao Corporation) was coated and dried to prepare a tablet. (2) Test method The test method was the same as in Example 3. From the setting of the measurement item, the measurement data of the tester is extracted and expressed as an average 値. The number of sets and testers is as follows. Neutral fat in the blood: neutral in the blood at the beginning of the intake | Testers with a fat fat of 150 mg/dL or more (n=8), systolic blood pressure, waist circumference and visceral fat area: visceral fat at the beginning of ingestion The tester with a sectional area of 1 〇〇 square centimeter or more (η = 1 〇), fasting blood glucose 値: the tester who had a blood glucose 値 above 85 mg/dL at the beginning of the intake (η = 8) ° During the ingestion period, 9 tablets were ingested per day as an ingredient (the scorpion acid content of 9 9 mg) described in Example 5 (1). The visceral fat sectional area was examined by abdominal CT scan, and abdominal fat accumulation was obtained from the umbilical tomographic image of φ during exhalation. (3) Results The results are shown in Table 3. The lozenge (the total amount of scorpion glucosinolate is 99 mg) described in Example 5 (1) was taken as one part, and the neutral fat sputum, systolic blood pressure, blood in the blood after 4 weeks was compared with the start of ingestion. The fasting blood glucose, waist circumference and visceral fat area decreased during fasting. The mulberry leaf has an α-glucosidase inhibitory effect and is known as a blood glucose sputum improving material. According to the literature (Food and Development VOL.37 No. 10, 54-56) -26-(24) (24)200803882 This effect was recognized by taking 1. 8 g. In addition, the literature describes that 1-deoxynojimycin, which is known to have an α-glucosidase inhibitory action, is contained in a test article containing 0.1% or more of the dried product, and 1 deoxynojirimycin in the literature. The daily intake is 1.8 mg. The mulberry leaf ingested as a one-day dosage in the test food was about 270 mg, and the daily intake of 1-deoxynojirimycin was 0.083 7 mg. Therefore, it is shown that the eucommia leaf has a lower amount of blood sputum than the known amount of mulberry leaves. [Table 3] Table 3 Metabolic syndrome of Eucommia ulmoides leaf extract, Eucommia ulmoides leaf powder and mulberry leaf extract. Blood neutral fat (mg/dL) after 4 weeks of ingestion at the beginning of ingestion 275.4 144.6* Systolic blood pressure (mm H g 142.1 132.7 Fasting blood glucose 空 (mg/dL) 92.0 89.5** Waist circumference (cm) 96.2 95.3 Visceral fat area (cm 2 ) 122.5 114.5** Note) Detection · *ρ<0·05 **ρ<0.01 [ Example 6] Evaluation test of metabolic syndrome improvement effect of Eucommia ulmoides leaf powder and indigestible dextrin (1) Preparation of test food test food system was prepared by mixing 62.5% by weight of the powder of Example 2 and 37.5 wt% of difficulty The powder of digestive dextrin (Fibersol 2: manufactured by Matsutani Chemical Industry Co., Ltd.) (8 g per bag, and the content of geniposide was I25 mg). (2) Test method -27- (25) (25) 200803882 The tester is based on 7 male and female adults. The test was conducted on the test food of Example 6 (1) and the indigestible dextrin, and a comparative test of postprandial blood glucose sputum was carried out. The tester was on a hunger strike at 22:00 the day before, and immediately after taking the initial blood glucose test at 9:00 every other day, immediately after taking 1 bag of the test food of Example 6 (1) or 5 g of the indigestible dextrin test food, respectively The diet of the same content was taken, and blood glucose levels of 30 minutes and 120 minutes after the meal were measured. In addition, the intake other than water is restricted until the end of the test. In the measurement of the blood glucose, the blood glucose was measured by a blood glucose meter (MED I SAFE MINI GR1 02: manufactured by Terumo Co., Ltd.) using a blood-sucking needle (Finetouch: manufactured by Terumo Co., Ltd.). . (3) Results The results are shown in Table 4. One bag of the powder of Example 6 (1) (the geniposide content was 125 mg) showed the same fasting blood glucose sputum as 5 g of the indigestible dextrin. It is known that indigestible dextrin does not inhibit disaccharide-decomposing enzymes such as fructosylase or maltase, and inhibits the absorption of glucose produced by hydrolysis of sucrose or maltose, thereby inhibiting the rise of blood sugar, and the literature (Japan Food Fiber Research Association) In VOL. 3 N0.1, 1 999, 1 57- 1 63), this effect is recognized based on the human intake of 5 g. In the test food, the indigestible dextrin which was ingested for one day was only 3 g, and the blood sugar was significantly improved by the use of the eucommia leaf. •28- (26) (26)200803882 [Table 4] Table 4 Postprandial blood glucose 値 improvement test food of test foods [1 glycoside (mg/dL) At the beginning of ingestion, after 30 minutes and after 120 minutes, Example 6 (1) 8 8.9 141.3 10 3.4 Indigestible dextrin 91.7 144.9 110.0 n = 7

-29-

Claims (1)

200803882 (1) X. Patent application scope 1 · A metabolic syndrome improvement agent characterized by containing a processed material of Eucommia ulmoides leaves. 2. The metabolic syndrome improving agent according to claim 1 of the patent application, further comprising a plant processed product having a blood sugar lowering effect. 3. The metabolic syndrome ameliorating agent according to claim 2, wherein the plant processing product is selected from the group consisting of indigestible dextrin and mulberry leaf processed material. 0. The metabolic syndrome modifier of claim 2, wherein the plant processing system has an alpha-glucosidase inhibitory action. 5. The metabolic syndrome improving agent according to any one of claims 2 to 4, wherein the plant processing is a plant extract. 6. The metabolic syndrome improving agent according to any one of claims 1 to 5, wherein the Eucommia leaf processing product is an extract of Eucommia ulmoides leaves. 7. The metabolic syndrome improving agent according to item 6 of the patent application, wherein the Eucommia leaf processing system comprises the steps of: steaming Eucommia leaves; the step of extracting Eucommia leaves by water extraction; and the step of concentrating the extract The eucommia leaf water extract obtained by the method. 8. The metabolic syndrome improving agent according to Item 6 or Item 7 of the patent application, wherein the Eucommia leaf processing system comprises the steps of: steaming the leaves of Eucommia ulmoides; the step of eucalyptus leaves; drying the leaves of Eucommia leaves; roasting a step of Eucommia ulmoides leaves; a step of extracting Eucommia leaves from water; and a Eucalyptus leaf water extract obtained by the method of concentrating the extract. 9. The metabolic syndrome improving agent of any one of claims 1 to 5 wherein the eucommia leaf processed material is dried cumin leaves -30-200803882 (2). 1 0. The metabolic syndrome improving agent of claim 9 wherein the pulverized material is a step comprising steaming Eucommia leaves; a step of eucommia ulmoides leaves; a step of drying Eucommia leaves; and a manufacturing method of pulverizing Eucommia leaves The resulting pulverized material. 1 1. The metabolic syndrome improving agent of claim 9 or claim 1, wherein the pulverized material is a step comprising steaming eucommia leaves; and drying the eucommia leaves under stirring and/or rolling; a step of homogenizing the water in the leaves of Eucommia ulmoides; a step of drying the leaves of Eucommia ulmoides; a step of pulverizing the leaves of Eucommia ulmoides; a step of irradiating the dried Eucommia leaves with far-infrared rays on the leaves of Eucommia; and a powder of Eucommia leaves by a jet mill The Eucommia leaf powder obtained by the manufacturing method of the step. 1 2 . The metabolic syndrome improving agent according to any one of claims 1 to 11, wherein the Eucommia ulmoides processed product is a mixture of Eucommia ulmoides leaf extract and dried Eucommia ulmoides leaves. The metabolic syndrome improving agent according to any one of the items 1 to 12, which contains 8 5 mg or more of geniposidic acid in a daily amount. The metabolic syndrome improving agent according to any one of claims 1 to 13, which is for use in the prevention of arteriosclerosis. A pharmaceutical composition comprising a metabolic syndrome ameliorating agent according to any one of claims 1 to 14. A food product comprising a metabolic syndrome improving agent according to any one of claims 1 to 14. -31 - 200803882 (3) 1 7. For the food of the 16th patent application, it is a functional food, a health food, a health supplement food, a nutritional supplement food, an insurance functional food, a specific insurance food or a nutritious functional food. . -32- 200803882 VII. Designated representative map: (1) The representative representative of the case is: None (2), the representative symbol of the representative figure is simple: no 8. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention: No. 200803883⁄4 When applying the barcode; • The patent application No. 96107288 replaces the pager _ 96 sounds August 28 曰 Revised invention patent specification (this application Book format, order and bold 765112 (2006.01) (2006,01) (2006.01) A2H oar ※Application number: 96107288 ※Application date: March 02, 1996 I. Name of the invention: (middle) metabolic syndrome improver (English), applicant: (1 in total) 1 Name: (中) Kobayashi Pharmaceutical Co., Ltd. (English) KOBAYASHI PHARMACEUTICAL CO·, LTD· Representative: (middle) 1. Kobayashi (" leather, 1 KORAYASHT ΥΙΓΓΑΚΑ Address: (f) Japan Osaka # Osaka City Center, Dao-cho, 4, Chome, San Francisco, No. 6 (English) 3-6, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 Japan Nationality: (Chinese-English) Japanese JAPAN III. Inventor: A total of 2 people) 馨1·Name··(中)平田哲也(英)HIRATA, TETSUYA Nationality: (中)Japan (English)JAPAN 2·Name: (中)安藤千穗(英)AND0, CHIH0 Nationality: (中)Japan (English) JAPAN IV. Declarations: ◎ Before applying for this patent, the following countries (regions) have applied for patents and claimed international priority: [Format please: Accepting country (region); application date; application number sequence Notes] 1·Japan; 2006/03/03; 2006-057825 Claims Priority 200803883⁄4 Text Sticking Barcode • Patent Application No. 96107288 Chinese Manual Replacement Page _ 96 Sounds August 28曰 Revised Invention Patent Specification (This application format, order and bold type 765112 (2006.01) (2006,01) (2006.01) A2H oar ※Application number: 96107288 ※Application date: March 02, 1996 I. Name of the invention: (middle) metabolic syndrome improver (English), applicant: (1 in total) 1 Name: (中) Kobayashi Pharmaceutical Co., Ltd. (English) KOBAYASHI PHARMACEUTICAL CO·, LTD· Representative: (middle) 1. Kobayashi (" leather, 1 KORAYASHT ΥΙΓΓΑΚΑ Address: (f) Japan Osaka # Osaka City Center, Dao-cho, 4, Chome, San Francisco, No. 6 (English) 3-6, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 Japan Nationality: (Chinese-English) Japanese JAPAN III. Inventor: A total of 2 people) 馨1·Name··(中)平田哲也(英)HIRATA, TETSUYA Nationality: (中)Japan (English)JAPAN 2·Name: (中)安藤千穗(英)AND0, CHIH0 Nationality: (中)Japan (English) JAPAN IV. Declarations: ◎ Before applying for this patent, the following countries (regions) have applied for patents and claimed international priority: [Format please: Accepting country (region); application date; application number sequence Notes] 1·Japan; 2006/03/03; 2006-057825 Claim priority